since initial FDA approval in AD2,a
Globally, ≈593,000 patients
treated
with DUPIXENT
worldwide across
5
indications1,b,c
a FDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and
2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe atopic dermatitis.2
b The worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China,
France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this
worldwide patient number. Data through January 2023.
c ≈323,000 US AD patients have filled at least 1 DUPIXENT prescription based on IQVIA National Source of Business (NSOB)
data as of December 2022.
Adults, aged 18+ years
The primary endpoint was the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16 (38% and 36% of patients treated with DUPIXENT vs 10% and 9% with placebo in SOLO 1 and SOLO 2, respectively, P<0.001; 39% of patients treated with DUPIXENT + TCS vs 12% with placebo + TCS in CHRONOS, P<0.0001). Other endpoints included the proportion of subjects with EASI-75 at Week 16 (51% and 44% of patients treated with DUPIXENT vs 15% and 12% with placebo in SOLO 1 and SOLO 2, respectively, P<0.001; 69% of patients treated with DUPIXENT + TCS vs 23% with placebo + TCS in CHRONOS, P<0.0001) and ≥4-point improvement in the Peak Pruritus NRS at Week 16 (41% and 36% of patients treated with DUPIXENT vs 12% and 10% with placebo in SOLO 1 and SOLO 2, respectively, P<0.001; 59% of patients treated with DUPIXENT + TCS vs 20% with placebo + TCS in CHRONOS, P<0.0001).2-4
917 adults in SOLO 1 and SOLO 2 (16 weeks each) and 421 adults in CHRONOS (52 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT or placebo. All patients in CHRONOS were treated with concomitant TCS. All patients who received DUPIXENT were given 300 mg Q2W after a 600 mg loading dose. Patients had an IGA score ≥3 on a scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and BSA involvement of ≥10%. At baseline, 52% had an IGA score of 3 (moderate), 48% had an IGA of 4 (severe), mean EASI score was 33, and weekly averaged Peak Pruritus NRS was 7 on a scale of 0 to 10.2
The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.2
BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.
Arsalan, age 29, living with moderate-to-severe atopic dermatitis
since 6 years of age
since 6 years of age
Currently taking DUPIXENT
I needed a long-term option. My arms were constantly itching. Topical Rxs didn't help. DUPIXENT does.
Real patient
being treated
with DUPIXENT.
Individual results
may vary.
My story
I’ve been seeing specialists for my moderate-to-severe atopic dermatitis since I was 6 years old. It was uncontrolled on topical Rx therapies. Itching was the worst, but since DUPIXENT, it’s more under control. My skin has noticeably cleared up.
My signs and symptoms
- Flare-ups started as red patches of itchy skin
- Red patches would transition into more white, discolored patches that were still itchy
- I would get patches all over my body and my skin would crack and bleed
My treatment and goals
- I tried a number of different holistic remedies
- Prescription allergy medications and topical corticosteroids
- Treatments worked for a while, but they stopped working—I needed an option that I could take continuously and would last
Jennifer, age 42, has sought treatment for uncontrolled moderate-to-severe atopic dermatitis since she was 5 years of age
Currently taking DUPIXENT
I tried topical Rxs and experienced
little relief until DUPIXENT. Now less
itch and clearer skin.
Real patient
being treated
with DUPIXENT.
Individual results
may vary.
My story
I was treated by a pediatrician starting at age 5 and later by a dermatologist. When they both ran out of ideas for my uncontrolled moderate-to-severe atopic dermatitis, I was referred to an allergist.
My signs and symptoms
- Persistent itch and cracking, peeling skin that would blister and ooze
- Lesions made it difficult for me to swim and perform musical theatre in costume
- My itch felt like a constant sunburn
My treatment and goals
- Oral and topical prescription steroids were not enough to help address the itch-scratch cycle
- I also tried immunosuppressants, UVB treatment 3 times a week, and bleach baths with no success
- I wanted itch relief—lasting change was my goal
Chloe, age 26, living with severe atopic dermatitis since 3 years of age
Currently taking DUPIXENT
I was always scratching my face as a baby and have had itchy skin since. With DUPIXENT, I finally feel a difference.
Real patient being treated
with DUPIXENT.
Individual results
may vary.
My story
I was 3 years old when my pediatrician diagnosed me with moderate-to-severe atopic dermatitis. It was uncontrolled on topical Rx therapies ever since and my biggest issue was itching. It’s hard to manage the constant itch!
My signs and symptoms
- Itchy skin and redness on ankles, back, elbows, feet, hands, knees, torso, and face
- Skin irritation affected me as a collegiate track runner
- Itch felt like bugs crawling on my skin and sometimes burning like fire
My treatment and goals
- Doctors prescribed oral and topical steroids throughout my life
- Steroids would work temporarily, but my skin would get even worse between treatment courses
- I challenged my doctors to find something else, something to help relieve the constant itch
Adolescents, aged 12-17 years
The primary endpoint was the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16 (24% of patients treated with DUPIXENT vs 2% with placebo, P<0.001). Other endpoints included the proportion of subjects with EASI-75 at Week 16 (42% of patients treated with DUPIXENT vs 8% with placebo, P<0.001) and ≥4-point improvement in the Peak Pruritus NRS at Week 16 (37% of patients treated with DUPIXENT vs 5% with placebo, P<0.001).2,5
251 adolescents (12-17 years) in AD-1526 (16 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose. Patients had an IGA score ≥3 on a scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and BSA involvement of ≥10%. At baseline, 46% had an IGA score of 3 (moderate), 54% had an IGA of 4 (severe), mean EASI score was 36, and weekly averaged Peak Pruritus NRS was 8 on a scale of 0 to 10.2
The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents observed through Week 52 was consistent with that seen in adults with atopic dermatitis.2
BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.
Tyler, age 14, has struggled with uncontrolled moderate-to-severe atopic dermatitis since infancy
Currently taking DUPIXENT – started in 2020
Topical Rxs weren't enough. With
DUPIXENT, his rashes faded, even
his feet are looking great!
-Tyler's parents
Real patient
being treated
with DUPIXENT.
Individual results
may vary.
Our story
Tyler has struggled to find control for his moderate-to-severe atopic dermatitis since infancy. Before DUPIXENT, despite using topical Rx therapies, nonstop itching and flares defined his childhood. We wanted his skin to get better with another treatment option.
His signs and symptoms
- Itching throughout the day
- Extremely dry, scaly skin with severe rashes—sensitive areas such as his feet were a real problem
- He had oozing and crusting skin
His treatment and goals
- Topical prescription therapies worked for awhile, but they stopped working and were damaging to his skin
- Chlorine baths and wet wraps were also ineffective
- We had to find another treatment that was appropriate for long-term use
Ore, age 15, living with moderate-to-severe atopic dermatitis
since childhood
since childhood
Currently taking DUPIXENT – started in 2019
We tried topical Rxs to clear her
skin, but they were not enough.
DUPIXENT made a difference.
-Ore's parents
Real patient
being treated
with DUPIXENT.
Individual results
may vary.
Our story
We went from dermatologist to dermatologist since she was a child. Finally, a dermatologist prescribed DUPIXENT for her uncontrolled moderate-to-severe atopic dermatitis. Now Ore can focus less on how to manage her skin.
Her signs and symptoms
- Constant itching along with dry patches
- Suffers from comorbid asthma currently managed with asthma medication
Her treatment and goals
- Creams, moisturizers, phototherapy, bleach baths, and more
- Diet change to help manage the sores and itching
- Topical prescription treatments would work for awhile, but were not enough
- We wanted to break the cycle of topical Rxs and spend less time managing her skin
Children, aged 6-11 years
The primary endpoint was the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) at Week 16 (39% of patients ≥30 kg treated with DUPIXENT + TCS vs 10% with placebo + TCS, and 30% of patients <30 kg treated with DUPIXENT + TCS vs 13% with placebo + TCS). Other endpoints included the proportion of subjects with EASI-75 at Week 16 (75% of patients ≥30 kg treated with DUPIXENT + TCS vs 26% with placebo + TCS, and 75% of patients <30 kg treated with DUPIXENT + TCS vs 28% with placebo + TCS) and ≥4-point improvement in the Peak Pruritus NRS at Week 16 (61% of patients ≥30 kg treated with DUPIXENT + TCS vs 13% with placebo + TCS, and 54% of patients <30 kg treated with DUPIXENT + TCS vs 12% with placebo + TCS).2,6
367 children (6-11 years) in AD-1652 (16 weeks) with severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT + TCS or placebo + TCS. Patients ≥30 kg but <60 kg received 200 mg Q2W after a 400 mg loading dose. Patients 15 kg but <30 kg received 300 mg Q4W after a 600 mg loading dose. Patients had an IGA score of 4, an EASI score ≥21, and BSA involvement ≥15%. Mean EASI score was 37.9 and weekly averaged Peak Pruritus NRS was 7.8 on a scale of 0 to 10.2
BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.
Harper, age 8, struggling with uncontrolled moderate-to-severe atopic dermatitis since early childhood
Currently taking DUPIXENT
Before DUPIXENT, Harper's hands
were a big problem. Topical Rxs
just weren't enough.
-Harper's parents
Real patient
being treated
with DUPIXENT.
Individual results
may vary.
Our story
After struggling with moderate-to-severe atopic dermatitis since early childhood, Harper was referred to a specialist by her primary care doctor when topical prescription therapies were not enough. We saw an allergist and a dermatologist. Now on DUPIXENT, Harper has less itching.
Her signs and symptoms
- Constant burning and itching that never went away
- Scratching throughout the night
- Puffy swollen eyes during a flare
- Her fingers and toes would bleed regularly
Her treatment and goals
- Treatments from oral and topical prescriptions to bleach baths and light therapy—all were unsuccessful
- We needed a treatment that could help reduce her itch and clear her skin
WATCH REAL PATIENTS'
STORIES WITH DUPIXENT
DUPIXENT and how it may be able to help
patients.